The ARFXF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARFXF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ARFXF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ARFXF Detailed Price Forecast - CNN Money||View ARFXF Detailed Summary - Google Finance|
|View ARFXF Detailed Summary - Yahoo! Finance||View ARFXF Stock Research & Analysis - Zacks.com|
|View ARFXF Trends & Analysis - Trade-Ideas||View ARFXF Major Holders - Barrons|
|View ARFXF Call Transcripts - NASDAQ||View ARFXF Breaking News & Analysis - Seeking Alpha|
|View ARFXF Annual Report - CompanySpotlight.com||View ARFXF OTC Short Report - OTCShortReport.com|
|View ARFXF Fundamentals - TradeKing||View ARFXF SEC Filings - Bar Chart|
|View Historical Prices for ARFXF - The WSJ||View Performance/Total Return for ARFXF - Morningstar|
|View the Analyst Estimates for ARFXF - MarketWatch||View the Earnings History for ARFXF - CNBC|
|View the ARFXF Earnings - StockMarketWatch||View ARFXF Buy or Sell Recommendations - MacroAxis|
|View the ARFXF Bullish Patterns - American Bulls||View ARFXF Short Pain Metrics - ShortPainBot.com|
|View ARFXF Stock Mentions - StockTwits||View ARFXF Stock Mentions - PennyStockTweets|
|View ARFXF Stock Mentions - Twitter||View ARFXF Investment Forum News - Investor Hub|
|View ARFXF Stock Mentions - Yahoo! Message Board||View ARFXF Stock Mentions - Seeking Alpha|
|View Insider Transactions for ARFXF - SECform4.com||View Insider Transactions for ARFXF - Insider Cow|
|View ARFXF Major Holdings Summary - CNBC||View Insider Disclosure for ARFXF - OTC Markets|
|View Insider Transactions for ARFXF - Yahoo! Finance||View Institutional Holdings for ARFXF - NASDAQ|
|View ARFXF Stock Insight & Charts - FinViz.com||View ARFXF Investment Charts - StockCharts.com|
|View ARFXF Stock Overview & Charts - BarChart||View ARFXF User Generated Charts - Trading View|
ProMIS Neurosciences to Participate in NobleCon15 and CanTech Investment Conferences
Posted on Thursday January 17, 2019
ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced that it will participate in the NobleCon15 and the CanTech Investment Conferences. Members of ProMIS’ senior management will provide overviews of its novel drug discovery and development programs for Alzheimer’s disease, Parkinson’s disease and ALS (amyotrophic lateral sclerosis), and participate on discussion panels.
PMN.TO: How Can ProMIS Contribute to the AD Treatment Setting?
Posted on Thursday January 03, 2019
The prevailing consensus on the cause of Alzheimer’s Disease (AD) has evolved over the last decades. In the 1980s, amyloid plaques or tau tangles were broadly but exclusively identified as the cause of the disease and the research community embarked on a search for a therapy that addressed one of these etiologies. In 1991 the amyloid hypothesis was proposed, further focusing development efforts.
ProMIS Neurosciences to Present at Sachs Associates Neuroscience Innovation Forum and China Focus@JPMWeek
Posted on Tuesday December 18, 2018
TORONTO and CAMBRIDGE, MA, Dec. 18, 2018 /PRNewswire/ - ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it will participate in several of the biotechnology industry's most well-attended annual conferences. At these events, company leadership will provide current and potential investors with an updated overview of its drug discovery and development programs for Alzheimer's, Parkinson's and ALS (amyotrophic lateral sclerosis).
ProMIS Neurosciences Appoints Renowned Neuroscientist, Dr. Rudolph Tanzi, to Scientific Advisory Board
Posted on Monday December 17, 2018
Dr. Tanzi is the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University and Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, and Co-Director of the Henry and Allison McCance Center for Brain Health at Massachusetts General Hospital.